Skip to content
OpenCapital
Get started

AN2 Therapeutics, Inc. ANTX Q1 2026 earnings

Reported May 11, 2026 · Before market open

EPS-$0.29Miss by $0.06
EPS estimate-$0.23

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.23

Versus estimates

Diluted EPS

Q1 2026-$0.29Miss by $0.06
Q4 2025-$0.29Miss by $0.05Q3 2025-$0.31Miss by $0.08Q2 2025-$0.21Beat by $0.10Q1 2025-$0.35Miss by $0.09Q4 2024-$0.25In line

Ask the moment AN2 Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did AN2 Therapeutics, Inc. report Q1 2026 earnings?
AN2 Therapeutics, Inc. (ANTX) reported Q1 2026 earnings on May 11, 2026 before market open.
What were AN2 Therapeutics, Inc.'s Q1 2026 revenue and EPS?
AN2 Therapeutics, Inc. reported eps of $-0.29 for Q1 2026.
Did AN2 Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.23 by $0.06.
How did AN2 Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 17.1% from $-0.35.
Where can I find AN2 Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-216752) and the 10-Q periodic report (0001193125-26-216755) directly on SEC EDGAR. The filing index links above go to sec.gov.